Aerovate Financial Statements From 2010 to 2025

AVTE Stock  USD 2.58  0.15  6.17%   
Aerovate Therapeutics financial statements provide useful quarterly and yearly information to potential Aerovate Therapeutics investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Aerovate Therapeutics financial statements helps investors assess Aerovate Therapeutics' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Aerovate Therapeutics' valuation are summarized below:
Market Capitalization
74.6 M
Earnings Share
(3.17)
There are over one hundred nineteen available fundamental signals for Aerovate Therapeutics, which can be analyzed over time and compared to other ratios. Investors should ensure to validate all of Aerovate Therapeutics' prevailing performance against the performance from 2010 to 2025 to make sure the company is sustainable down the road. As of January 18, 2025, Market Cap is expected to decline to about 423.9 M. In addition to that, Enterprise Value is expected to decline to about 407.8 M
Check Aerovate Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Aerovate Therapeutics' main balance sheet or income statement drivers, such as Net Interest Income of 6.2 M, Depreciation And Amortization of 115.9 K or Interest Expense of 2.1 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 5.14. Aerovate financial statements analysis is a perfect complement when working with Aerovate Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Aerovate Therapeutics Correlation against competitors.
For information on how to trade Aerovate Stock refer to our How to Trade Aerovate Stock guide.

Aerovate Therapeutics Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets98.2 M146.5 M45.2 M
Slightly volatile
Short and Long Term Debt Total967.8 K607.5 K1.8 M
Slightly volatile
Other Current Liabilities17.9 M17 M3.6 M
Slightly volatile
Total Current Liabilities21.3 M20.3 M4.9 M
Slightly volatile
Accounts Payable1.6 M2.8 MM
Slightly volatile
Cash23.8 M27 M11.9 M
Slightly volatile
Long Term DebtM2.2 M2.5 M
Slightly volatile
Cash And Short Term Investments94 M140.8 M43.3 M
Slightly volatile
Common Stock Shares Outstanding27.3 M30.3 M25.1 M
Slightly volatile
Liabilities And Stockholders Equity98.2 M146.5 M45.2 M
Slightly volatile
Non Current Liabilities Total277.9 K292.5 K5.2 M
Slightly volatile
Total Liabilities12 M20.7 M9.5 M
Slightly volatile
Total Current Assets96.4 M142.9 M44.3 M
Slightly volatile
Net Working Capital89.7 M122.6 M40.4 M
Slightly volatile
Other Current Assets3.1 M2.1 M1.1 M
Slightly volatile
Property Plant Equipment421.9 K837.2 K242 K
Slightly volatile
Other Liabilities46.2 K81.7 K26.6 K
Slightly volatile
Current Deferred Revenue805.6 K906.3 K988.1 K
Slightly volatile
Non Currrent Assets Other1.9 M2.6 M811.3 K
Slightly volatile
Non Current Liabilities Other56.5 K80.5 K27.1 K
Slightly volatile
Short Term Debt577.1 K483 K428.6 K
Slightly volatile
Common Stock2.6 K3.5 K2.2 K
Slightly volatile

Aerovate Therapeutics Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization115.9 K110.4 K26 K
Slightly volatile
Selling General Administrative20.8 M19.8 M5.2 M
Slightly volatile
Other Operating Expenses98.3 M93.6 M24.5 M
Slightly volatile
Research Development77.5 M73.9 M19.3 M
Slightly volatile
Total Operating Expenses98.3 M93.6 M24.5 M
Slightly volatile
Cost Of Revenue115.9 K110.4 K26 K
Slightly volatile
Interest Income6.2 M5.9 M1.2 M
Slightly volatile
Selling And Marketing Expenses76.8 K86.4 K94.2 K
Slightly volatile

Aerovate Therapeutics Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Net BorrowingsM2.2 M2.5 M
Slightly volatile
Begin Period Cash Flow19.5 M25.8 M10.5 M
Slightly volatile
Other Cashflows From Financing Activities1.9 MM8.3 M
Pretty Stable
Depreciation115.9 K110.4 K26 K
Slightly volatile
Capital Expenditures140.8 K127.8 K173.6 K
Slightly volatile
Total Cash From Financing Activities54.6 M52.9 M23.6 M
Slightly volatile
End Period Cash Flow23.8 M27 M11.9 M
Slightly volatile
Change To Netincome5.5 M5.3 M1.9 M
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Capex To Depreciation1.621.79.5292
Slightly volatile
Payables Turnover0.03790.03610.0107
Slightly volatile
Cash Per Share2.744.181.5834
Slightly volatile
Days Payables Outstanding19.2 K10.5 K25.3 K
Slightly volatile
Income Quality0.960.860.8558
Pretty Stable
Net Debt To EBITDA0.310.320.5814
Very volatile
Current Ratio6.026.3410.0493
Pretty Stable
Graham Number7.5414.744.7156
Slightly volatile
Capex Per Share0.00760.00620.0073
Slightly volatile
Interest Debt Per Share0.04440.02950.0748
Slightly volatile
Debt To Assets0.00580.00610.4466
Slightly volatile
Days Of Payables Outstanding19.2 K10.5 K25.3 K
Slightly volatile
Ebt Per Ebit1.091.071.0081
Pretty Stable
Quick Ratio6.026.3410.0493
Pretty Stable
Net Income Per E B T0.790.90.9398
Pretty Stable
Cash Ratio1.461.535.2823
Pretty Stable
Free Cash Flow Operating Cash Flow Ratio1.11.151.021
Slightly volatile
Debt Ratio0.00580.00610.4466
Slightly volatile

Aerovate Therapeutics Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap423.9 M645.3 M557.6 M
Very volatile
Enterprise Value407.8 M626.2 M548.4 M
Very volatile

Aerovate Fundamental Market Drivers

Cash And Short Term Investments122.4 M

Aerovate Upcoming Events

3rd of April 2024
Upcoming Quarterly Report
View
20th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
3rd of April 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Aerovate Therapeutics Financial Statements

Aerovate Therapeutics stakeholders use historical fundamental indicators, such as Aerovate Therapeutics' revenue or net income, to determine how well the company is positioned to perform in the future. Although Aerovate Therapeutics investors may analyze each financial statement separately, they are all interrelated. For example, changes in Aerovate Therapeutics' assets and liabilities are reflected in the revenues and expenses on Aerovate Therapeutics' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Aerovate Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue906.3 K805.6 K
Cost Of Revenue110.4 K115.9 K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Aerovate Therapeutics is a strong investment it is important to analyze Aerovate Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Aerovate Therapeutics' future performance. For an informed investment choice regarding Aerovate Stock, refer to the following important reports:
Check out the analysis of Aerovate Therapeutics Correlation against competitors.
For information on how to trade Aerovate Stock refer to our How to Trade Aerovate Stock guide.
You can also try the Risk-Return Analysis module to view associations between returns expected from investment and the risk you assume.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Aerovate Therapeutics. If investors know Aerovate will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Aerovate Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(3.17)
Return On Assets
(0.49)
Return On Equity
(0.82)
The market value of Aerovate Therapeutics is measured differently than its book value, which is the value of Aerovate that is recorded on the company's balance sheet. Investors also form their own opinion of Aerovate Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Aerovate Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Aerovate Therapeutics' market value can be influenced by many factors that don't directly affect Aerovate Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Aerovate Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Aerovate Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Aerovate Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.